A POST MARKETING SURVEILLANCE STUDY TO EVALUATE THE SAFETY AND EFFICACY of PANKAJAKASTHURI BREATHE EAZY GRANULES AND SYRUP

RETROSPECTIVE, CROSS SECTIONAL AND PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE PANKAJAKASTHURI BREATHE EAZY GRANULES AND SYRUP THROUGH POST MARKETING SURVEILLANCE STUDY

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/07/034636

Enrollment

1500

Registered

2021-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J40-J47- Chronic lower respiratory diseases Health Condition 2: J20-J22- Other acute lower respiratory infections Health Condition 3: J96-J99- Other diseases of the respiratory system Health Condition 4: J30-J39- Other diseases of upper respiratory tract

Interventions

Intervention1: Breathe Eazy granules and syrup: Pankajakasthuri Breathe Eazy Granules- 15 gms (1 table spoon) twice daily after food. Pankajakasthuri Breathe Eazy syrup-1 table spoon thrice daily afte

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 19 Years and above 2. Subjects who have participated in the retrospective cross-sectional PMS of Breathe eazy granules and syrup. 3. Patients willing to take Breathe Eazy granules and syrup in a dose of 1 table spoon twice daily after food continuously for a minimum period of 3 months. 4. Subjects who have started taking Breathe Eazy granules and syrup at least for last 3 months. 5. Subjects willing to enroll in study by signing Informed consent. 6. Subjects presenting with Allergic bronchitis, Allergic rhinitis, COPD, Sinusitis, Eosinophilia and other Respiratory tract infections.

Exclusion criteria

Exclusion criteria: 1. Subjects who have not taken Breathe Eazy granules and syrup in the prescribed dose and duration. 2. Diagnosed patients of Diabetes Mellitus (DM)

Design outcomes

Primary

Measure	Time frame
Any marked change in safety parameters measured during the administration of the product. â?¢ Reporting the effectiveness of this product in the management of Allergic bronchitis, Allergic rhinitis, COPD, Sinusitis, Eosinophilia and other Respiratory tract infections and associated complaints. Timepoint: oth-baseline1st-first response to questionnaire and 2nd-response at the end of the study	—

Secondary

Measure	Time frame
Additional therapeutic advantages of the productTimepoint: oth-baseline1st-first response to questionnaire and 2nd-response at the end of the study	—

Countries

India

Contacts

Public ContactMr Arun Visakh Nair

Pankajakasthuri Herbal research Foundation

drshan@phkil.com9188325339

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026